2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N6033
    Ferruginol 514-62-5
    Ferruginol ((+)-Ferruginol), a natural diterpenoid, is an inhibitor of the activation of Epstein-Barr virus early antigen (EBV-EA). Ferruginol inhibits the growth of thyroid cancer cells through the induction of mitochondrial apoptosis. Ferruginol has antitumor, cardioprotective, antioxidant, gastroprotective, and neuroprotective activities.
    Ferruginol
  • HY-N6043
    Hydroxytyrosol acetate 69039-02-7 98.10%
    Hydroxytyrosol acetate is a prodrug of Hydroxytyrosol (HY-N0570). Hydroxytyrosol acetate is converted into the active form of Hydroxytyrosol in vivo. Hydroxytyrosol is a phenol found in the olive oil. Hydroxytyrosol can alleviate oxidative stress and improve mitochondrial function, thereby exerting neuroprotective effects. Hydroxytyrosol can induce cancer cells apoptosis via inducing ROS production. Hydroxytyrosol shows antibacterial and antiviral effect. Hydroxytyrosol can be used for the researches of cancer, infection, inflammation, immunology, metabolic, neurological and cardiovascular disease, such as colon cancer, diabetes, Alzheimer's Disease and atherosclerosis .
    Hydroxytyrosol acetate
  • HY-N6868
    Dimethyl lithospermate B 875313-64-7 99.40%
    Dimethyl lithospermate B (dmLSB) is a selective Na+ channel agonist. Dimethyl lithospermate B slows inactivation of sodium current (INa), leading to increased inward current during the early phases of the action potential (AP).
    Dimethyl lithospermate B
  • HY-N7064
    Iminostilbene 256-96-2 99.34%
    Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases.
    Iminostilbene
  • HY-N7607
    Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside 143016-74-4 99.87%
    Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside is a flavonoid glycoside with antioxidant activity and free radical scavenging activity. Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside can scavenge free radicals such as ABTS+ and can be used in the study of antioxidant-related diseases (such as cardiovascular diseases and neurodegenerative diseases).
    Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside
  • HY-P1469
    Bradykinin (1-6) 23815-88-5 99.60%
    Bradykinin (1-6) is an amino-truncated Bradykinin peptide. Bradykinin (1-6) is a stable metabolite of Bradykinin, cleaved by carboxypeptidase Y (CPY).
    Bradykinin (1-6)
  • HY-P1525
    Melanin Concentrating Hormone, salmon 87218-84-6 99.09%
    Melanin Concentrating Hormone, salmon is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.
    Melanin Concentrating Hormone, salmon
  • HY-P1770
    Adrenomedullin (16-31), human 318480-38-5 98.50%
    Adrenomedullin (16-31), human is amino acid residues 16-31 fragment of human adrenomedullin (hADM). Adrenomedullin has appreciable affinity for the CGRP1 receptor. Adrenomedullin (16-31), human possesses pressor activity in the systemic vascular bed of the rat, but not the cat.
    Adrenomedullin (16-31), human
  • HY-P4764
    Ac-(d-Arg)-CEH-(d-Phe)-RWC-NH2 819048-44-7 99.09%
    Ac-DArg-c[Cys-Glu-His-DPhe-Arg-Trp-Cys]-NH 2 is a cyclic octapeptide with MC4R agonism. Ac-DArg-c[Cys-Glu-His-DPhe-Arg-Trp-Cys]-NH 2 significantly increases heart rate and blood pressure.
    Ac-(d-Arg)-CEH-(d-Phe)-RWC-NH2
  • HY-P4987
    TRAP-7 145229-76-1 99.66%
    TRAP-7 is a thrombin receptor (PAR) activating peptide. TRAP-7 stimulates total inositol phosphate (IP) accumulation and phosphorylation of a specific endogenous substrate for activated PKC. TRAP-7 can be used in cardiovascular disease research.
    TRAP-7
  • HY-P5881
    PKCα (C2-4) inhibitor peptide 99.81%
    PKCα (C2-4) inhibitor peptide is a PKCα specific inhibitor peptide that blocks the inhibition of IKr by the α1A adrenoreceptor agonist A-61603 (HY-101366).
    PKCα (C2-4) inhibitor peptide
  • HY-Z0075
    (Z)2S,4R-Sacubitril
    (Z)2S,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and agent Administration for use in combination with valsartan for the treatment of patients with heart failure.
    (Z)2S,4R-Sacubitril
  • HY-100315
    XL 999 705946-27-6 99.01%
    XL999 is a multi-target tyrosine kinase inhibitor. XL999 has IC50 values for KDR, Flt-1, FGFR1 and PDGFRα of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer.
    XL 999
  • HY-100933
    MY-5445 78351-75-4 ≥99.0%
    MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, phosphodiesterase type 5 (PDE5), with a Ki of 1.3 μM. MY-5445 inhibits human platelet aggregation. MY-5445 is a selective modulator of ATP-binding cassette (ABC) transporter ABCG2, with anti-proliferative effect.
    MY-5445
  • HY-101232
    Tiotidine 69014-14-8 99.28%
    Tiotidine (ICI 125211) is a potent and selective antagonist of histamine H2-receptor (pA2=7.3-7.8 for guinea-pig right atrium). Tiotidine has low affinity for both the H1 and the H3 receptors.
    Tiotidine
  • HY-101237
    DHBP dibromide 6159-05-3 99.17%
    DHBP dibromide is an inhibitor for calcium release and a muscle relaxant.
    DHBP dibromide
  • HY-101656
    Medroxalol 56290-94-9 99.85%
    Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects.
    Medroxalol
  • HY-103136
    R-96544 167144-80-1 ≥99.5%
    R-96544 is an orally active 5-HT2A receptor antagonist. R-96544 can inhibit platelet aggregation in vitro.
    R-96544
  • HY-103263
    PSB-06126 1052089-16-3 99.86%
    PSB-06126 is a selective nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitor, with the Ki values of 0.33 μM for rat NTPDase 1, 19.1 μM for NTPDase 2 and 2.22 μM for NTPDase 3, respectively. PSB-06126 acts on human NTPDase 3 with an IC50 value of 7.76 μM and a Ki value of 4.39 μM.
    PSB-06126
  • HY-103462
    TC-F2 1304778-15-1 99.35%
    TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders.
    TC-F2
Cat. No. Product Name / Synonyms Application Reactivity